Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.50 |
| ▸ | PDE4A | P27815 | 7/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.50 |
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084187 | 1.00 | CA1 (0.59) | CA1CA2ACHEPDE4BPDE4A | |
| SCHEMBL905907 | 1.00 | CA1 (0.59) | CA1CA2ACHEPDE4BPDE4A | |
| Levacetylleucine SCHEMBL7085506 | 0.83 | LMNA (0.47) | CA1CA2ACHEPDE4BPDE4A | |
| Levacetylleucine SCHEMBL906113 | 0.83 | LMNA (0.47) | CA1CA2ACHEPDE4BPDE4A | |
| Levacetylleucine SCHEMBL18263873 | 0.83 | LMNA (0.47) | CA1CA2ACHEPDE4BPDE4A | |
| SCHEMBL6876864 | 0.82 | PDE4B (0.54) | CA1CA2ACHEPDE4BPDE4A | |
| SCHEMBL18191195 | 0.82 | CA1 (0.42) | CA1CA2ACHEPDE4BPDE4A | |
| Ammonia Solution, Strong SCHEMBL18920443 | 0.81 | PDE4B (0.53) | CA1CA2ACHEPDE4BPDE4A | |
| Hydrochloric Acid SCHEMBL7618320 | 0.81 | ALDH1A1 (0.51) | CA1CA2ACHEPDE4BPDE4A | |
| SCHEMBL23365792 | 0.80 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016174685-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2016-11-03 | — | — | WO | claimed |
| EP-3341359-A1 | PROCESS FOR PREPARATION OF APREMILAST | Glenmark Pharmaceuticals Limited (IN) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-3142663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-3142748-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017033116-A1 | PROCESS FOR PREPARATION OF APREMILAST | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016174685-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2016-11-03 | — | — | WO | disclosed |
| WO-2015175773-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CELGENE CORPORATION (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015175956-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2935226-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014100748-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2701701-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Celgene Corporation (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2683376-A2 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012149251-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | CELGENE CORPORATION (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012121988-A2 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2012-09-13 | — | — | WO | disclosed |
| EP-2223687-A1 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof | CELGENE CORPORATION (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1965793-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079182-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |